CHK-336

CHK-336 is an orally administered small molecule inhibitor of lactate dehydrogenase A (LDHA), developed for the treatment of primary hyperoxaluria and other kidney stone disorders driven by endogenous overproduction of oxalate. The drug acts by inhibiting LDHA, the final enzymatic step in hepatic oxalate synthesis, thereby reducing hepatic oxalate production and urinary oxalate excretion. Preclinical studies demonstrated significant reductions in urinary oxalate in mouse models of primary hyperoxaluria types 1 and 2. In phase 1 clinical trials, CHK-336 showed dose-proportional pharmacokinetics with a half-life supporting once-daily dosing and was generally well tolerated at single doses up to 500 mg and multiple doses up to 60 mg daily for 14 days; however, a serious adverse event (anaphylaxis) occurred at a higher dose leading to voluntary pausing of the trial. The program was initiated by Chinook Therapeutics, which has since been acquired by Novartis[3][4][5][6][7].

Other names

CHK 336CHK336CHK-336